Corneal pseudomicrocysts following claudin-6 antibody-drug conjugate infusion
Purpose: To report a case of bilateral corneal pseudomicrocysts associated with infusions of a novel antibody-drug conjugate targeting claudin-6, called TORL-1-23. Observations: A 47-year-old female with a history of advanced recurrent serous ovarian cancer presented to a level 1 tertiary care cente...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-09-01
|
| Series: | American Journal of Ophthalmology Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2451993625001288 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839638683180859392 |
|---|---|
| author | Laura Matuszewska Caitlynn Cooper Victoria Sattarova Wassef Chanbour Evan Meyer Vania Rashidi |
| author_facet | Laura Matuszewska Caitlynn Cooper Victoria Sattarova Wassef Chanbour Evan Meyer Vania Rashidi |
| author_sort | Laura Matuszewska |
| collection | DOAJ |
| description | Purpose: To report a case of bilateral corneal pseudomicrocysts associated with infusions of a novel antibody-drug conjugate targeting claudin-6, called TORL-1-23. Observations: A 47-year-old female with a history of advanced recurrent serous ovarian cancer presented to a level 1 tertiary care center with ocular irritation, redness, tearing, and light sensitivity following two infusions of TORL-1-23. Patient's past ocular history was unremarkable. The patient was enrolled in a phase 1 clinical trial for TORL-1-23, an antibody-drug conjugate (ADC). Nine days following the second infusion the patient presented to the ophthalmology clinic complaining of two weeks of bilateral eye discomfort, tearing, and photophobia. On examination, the patient had decreased visual acuity with a surface keratopathy associated with a whorled pattern of epithelial pseudomicrocysts in both eyes. Corneal changes were concentrated between the inferior limbus and central cornea. The remainder of the ophthalmic exam was unremarkable. Collagen and silicone punctal plugs were placed and the patient was started on preservative free artificial tears, topical loteprednol 0.5 %, later replaced with topical prednisolone acetate 1 % drops, and brimonidine 0.2 % in both eyes. The patient developed neuropathy which necessitated a decrease in ADC dosage and the patient's symptoms subsequently improved. However, a decrease in visual acuity and increase in corneal pseudomicrocysts was seen after the fifth infusion. Corneal disease improved with the placement of new collagen punctal plugs and addition of cyclosporine 0.05 % eye drops in both eyes. Ocular symptoms and exam findings waxed and waned with continued infusions of the ADC. Conclusions and importance: This case reports an incidence of corneal pseudomicrocysts associated with TORL-1-23 treatment, which should be recognized as a potential adverse effect of this novel therapy. |
| format | Article |
| id | doaj-art-a85a859a04e84a089e2ce1e726299854 |
| institution | Matheson Library |
| issn | 2451-9936 |
| language | English |
| publishDate | 2025-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Journal of Ophthalmology Case Reports |
| spelling | doaj-art-a85a859a04e84a089e2ce1e7262998542025-07-05T04:47:22ZengElsevierAmerican Journal of Ophthalmology Case Reports2451-99362025-09-0139102375Corneal pseudomicrocysts following claudin-6 antibody-drug conjugate infusionLaura Matuszewska0Caitlynn Cooper1Victoria Sattarova2Wassef Chanbour3Evan Meyer4Vania Rashidi5Kansas City University College of Osteopathic Medicine, 1750 Independence Avenue, Kansas City, MO, 64106, USA; University of Minnesota Medical School, 420 Delaware St SE, Minneapolis, MN, 55455, USAUniversity of Minnesota Medical School, 420 Delaware St SE, Minneapolis, MN, 55455, USA; Hennepin Healthcare, 715 South 8th St, Minneapolis, MN, 55404, USA; University of Minnesota, Department of Ophthalmology and Visual Neurosciences, 516 Delaware St SE, Minneapolis, MN, 55455, USAHennepin Healthcare, 715 South 8th St, Minneapolis, MN, 55404, USA; University of Minnesota, Department of Ophthalmology and Visual Neurosciences, 516 Delaware St SE, Minneapolis, MN, 55455, USAUniversity of Minnesota Medical School, 420 Delaware St SE, Minneapolis, MN, 55455, USA; University of Minnesota, Department of Ophthalmology and Visual Neurosciences, 516 Delaware St SE, Minneapolis, MN, 55455, USAUniversity of Minnesota Medical School, 420 Delaware St SE, Minneapolis, MN, 55455, USA; Hennepin Healthcare, 715 South 8th St, Minneapolis, MN, 55404, USA; University of Minnesota, Department of Ophthalmology and Visual Neurosciences, 516 Delaware St SE, Minneapolis, MN, 55455, USAUniversity of Minnesota Medical School, 420 Delaware St SE, Minneapolis, MN, 55455, USA; University of Minnesota, Department of Ophthalmology and Visual Neurosciences, 516 Delaware St SE, Minneapolis, MN, 55455, USA; Corresponding author. 516Delaware St SE, Minneapolis, MN, 55455.USA.Purpose: To report a case of bilateral corneal pseudomicrocysts associated with infusions of a novel antibody-drug conjugate targeting claudin-6, called TORL-1-23. Observations: A 47-year-old female with a history of advanced recurrent serous ovarian cancer presented to a level 1 tertiary care center with ocular irritation, redness, tearing, and light sensitivity following two infusions of TORL-1-23. Patient's past ocular history was unremarkable. The patient was enrolled in a phase 1 clinical trial for TORL-1-23, an antibody-drug conjugate (ADC). Nine days following the second infusion the patient presented to the ophthalmology clinic complaining of two weeks of bilateral eye discomfort, tearing, and photophobia. On examination, the patient had decreased visual acuity with a surface keratopathy associated with a whorled pattern of epithelial pseudomicrocysts in both eyes. Corneal changes were concentrated between the inferior limbus and central cornea. The remainder of the ophthalmic exam was unremarkable. Collagen and silicone punctal plugs were placed and the patient was started on preservative free artificial tears, topical loteprednol 0.5 %, later replaced with topical prednisolone acetate 1 % drops, and brimonidine 0.2 % in both eyes. The patient developed neuropathy which necessitated a decrease in ADC dosage and the patient's symptoms subsequently improved. However, a decrease in visual acuity and increase in corneal pseudomicrocysts was seen after the fifth infusion. Corneal disease improved with the placement of new collagen punctal plugs and addition of cyclosporine 0.05 % eye drops in both eyes. Ocular symptoms and exam findings waxed and waned with continued infusions of the ADC. Conclusions and importance: This case reports an incidence of corneal pseudomicrocysts associated with TORL-1-23 treatment, which should be recognized as a potential adverse effect of this novel therapy.http://www.sciencedirect.com/science/article/pii/S2451993625001288Antibody-drug conjugateCorneal opacity |
| spellingShingle | Laura Matuszewska Caitlynn Cooper Victoria Sattarova Wassef Chanbour Evan Meyer Vania Rashidi Corneal pseudomicrocysts following claudin-6 antibody-drug conjugate infusion American Journal of Ophthalmology Case Reports Antibody-drug conjugate Corneal opacity |
| title | Corneal pseudomicrocysts following claudin-6 antibody-drug conjugate infusion |
| title_full | Corneal pseudomicrocysts following claudin-6 antibody-drug conjugate infusion |
| title_fullStr | Corneal pseudomicrocysts following claudin-6 antibody-drug conjugate infusion |
| title_full_unstemmed | Corneal pseudomicrocysts following claudin-6 antibody-drug conjugate infusion |
| title_short | Corneal pseudomicrocysts following claudin-6 antibody-drug conjugate infusion |
| title_sort | corneal pseudomicrocysts following claudin 6 antibody drug conjugate infusion |
| topic | Antibody-drug conjugate Corneal opacity |
| url | http://www.sciencedirect.com/science/article/pii/S2451993625001288 |
| work_keys_str_mv | AT lauramatuszewska cornealpseudomicrocystsfollowingclaudin6antibodydrugconjugateinfusion AT caitlynncooper cornealpseudomicrocystsfollowingclaudin6antibodydrugconjugateinfusion AT victoriasattarova cornealpseudomicrocystsfollowingclaudin6antibodydrugconjugateinfusion AT wassefchanbour cornealpseudomicrocystsfollowingclaudin6antibodydrugconjugateinfusion AT evanmeyer cornealpseudomicrocystsfollowingclaudin6antibodydrugconjugateinfusion AT vaniarashidi cornealpseudomicrocystsfollowingclaudin6antibodydrugconjugateinfusion |